These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Predicting drug-free improvement in schizophrenic psychosis. Marder SR; van Kammen DP; Docherty JP; Rayner J; Bunney WE Arch Gen Psychiatry; 1979 Sep; 36(10):1080-5. PubMed ID: 38763 [TBL] [Abstract][Full Text] [Related]
43. [THE USE OF A BUTYROPHENONE NEUROLEPTIC (HALOPERIDOL) IN ACUTE AND CHRONIC PSYCHOSES]. MADALENA JC; FERREIRA LR; BELLO H Rev Assoc Med Bras; 1963; 9():375-86. PubMed ID: 14163287 [No Abstract] [Full Text] [Related]
44. Differential therapeutic response by history during treatment with neuroleptic threshold haloperidol doses. McEvoy JP; Stiller RL; Everett GR J Clin Psychopharmacol; 1987 Oct; 7(5):368-9. PubMed ID: 3680618 [No Abstract] [Full Text] [Related]
45. Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients. Ravn J Acta Psychiatr Scand; 1987 Nov; 76(5):605. PubMed ID: 2893514 [No Abstract] [Full Text] [Related]
46. Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria. Ezeme MS; Uwakwe R; Ndukuba AC; Igwe MN; Odinka PC; Amadi K; Obayi NO Afr Health Sci; 2016 Dec; 16(4):1036-1044. PubMed ID: 28479897 [TBL] [Abstract][Full Text] [Related]
47. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Dold M; Samara MT; Li C; Tardy M; Leucht S Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299 [TBL] [Abstract][Full Text] [Related]
49. The long-term effects of placebo in patients with chronic schizophrenia. Wyatt RJ; Henter ID; Bartko JJ Biol Psychiatry; 1999 Oct; 46(8):1092-105. PubMed ID: 10536745 [TBL] [Abstract][Full Text] [Related]
50. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346 [TBL] [Abstract][Full Text] [Related]
51. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Nedopil N; Pflieger R; Rüther E Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576 [TBL] [Abstract][Full Text] [Related]
52. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients]. Möller HJ; Scharl W; von Zerssen D Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152 [TBL] [Abstract][Full Text] [Related]
53. [Modification of long-term schizophrenia by somato-therapeutic measures]. Gross G; Huber G; Schüttler R Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621 [TBL] [Abstract][Full Text] [Related]
54. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
55. Initial improvement as predictor of outcome of neuroleptic treatment. Nedopil N; Rüther E Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712 [TBL] [Abstract][Full Text] [Related]